US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of ...

New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SP ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...

Law enforcement officers are conducting searches in case of possible fraud during fundraising for the treatment of spinal ...

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...

Sarcopenia, which is a progressive and extensive decline in muscle mass and strength, is common with aging and is estimated ...

Living with SMA isn't just about survival, says columnist. There's also the emotional weight of preparing for the next crisis ...

Panelists discuss how communication between clinicians, patients, and payers could improve equitable access to spinal ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

In a Phase I study, previously treated pediatric SMA patients exhibited reductions in a marker of neurodegeneration after salanersen treatment.